Literature DB >> 15557758

The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship?

Mahmoud R Hussein1.   

Abstract

Mutations in the TP53 gene are found in about 11% of melanomas. Although nearly 600 papers have been published with varying degrees of consensus, there does not appear to be any comparable analysis that facilitates more than a glimpse into the role of p53 in melanomagenesis. This article reviews p53 alterations (at the gene and protein levels) in melanocytic skin lesions and discusses the following points: (i) p53 alterations commence as early as at the stage of benign and dysplastic nevi; (ii) these alterations are frequent in melanomas, and gradually increase with their progression; (iii) there is no concordance between the frequent p53 protein expression and the rarity of both TP53 gene mutations in melanomas, and (iv) the entire p53 pathway is a more critical determinant of the fate of the melanocytic skin lesions than the status of the p53 protein or the gene itself.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557758     DOI: 10.1159/000081103

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  5 in total

1.  Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas.

Authors:  Mahmoud R Hussein; Rabab M H El-Ghorori; Yasser G Abd El-Rahman
Journal:  Int J Exp Pathol       Date:  2006-08       Impact factor: 1.925

2.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

3.  Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.

Authors:  Cyrille J Cohen; Zhili Zheng; Regina Bray; Yangbing Zhao; Linda A Sherman; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

4.  Nuclear ING2 expression is reduced in human cutaneous melanomas.

Authors:  F Lu; D L Dai; M Martinka; V Ho; G Li
Journal:  Br J Cancer       Date:  2006-06-06       Impact factor: 7.640

Review 5.  Role of insulin-like growth factor 1 receptor signalling in cancer.

Authors:  O Larsson; A Girnita; L Girnita
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.